SFG
CNTX icon

Strive Financial Group’s Context Therapeutics CNTX Stock Holding History

Strive Financial Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942 Hold
1,700
– – ﹤0.01% 704
2026
Q1 		$4K Hold
1,700
– – ﹤0.01% 541
2025
Q4 		$2.5K Buy
+1,700
New +$1.99K ﹤0.01% 557

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Strive Financial Group's CNTX Position: Q2 2026 in Review

Strive Financial Group held its Context Therapeutics (CNTX) position steady in Q2 2026 at 1,700 shares worth $942. The position accounts for ﹤0.01% of the portfolio, ranked #704.

Strive Financial Group first reported a position in CNTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $4K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Strive Financial Group held 1,700 shares of Context Therapeutics worth $942 as of Q2 2026.
  • Strive Financial Group left its Context Therapeutics share count unchanged in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Strive Financial Group's portfolio in Q2 2026, its #704 holding.
  • Strive Financial Group first reported a position in Context Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Strive Financial Group's Context Therapeutics position peaked at $4K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.